These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

393 related articles for article (PubMed ID: 21415163)

  • 1. Metformin decreases the dose of chemotherapy for prolonging tumor remission in mouse xenografts involving multiple cancer cell types.
    Iliopoulos D; Hirsch HA; Struhl K
    Cancer Res; 2011 May; 71(9):3196-201. PubMed ID: 21415163
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission.
    Hirsch HA; Iliopoulos D; Tsichlis PN; Struhl K
    Cancer Res; 2009 Oct; 69(19):7507-11. PubMed ID: 19752085
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metformin inhibits the inflammatory response associated with cellular transformation and cancer stem cell growth.
    Hirsch HA; Iliopoulos D; Struhl K
    Proc Natl Acad Sci U S A; 2013 Jan; 110(3):972-7. PubMed ID: 23277563
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combining naringenin and metformin with doxorubicin enhances anticancer activity against triple-negative breast cancer in vitro and in vivo.
    Pateliya B; Burade V; Goswami S
    Eur J Pharmacol; 2021 Jan; 891():173725. PubMed ID: 33157041
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhanced therapeutic effects of doxorubicin and paclitaxel in combination with liposome-entrapped ends-modified raf antisense oligonucleotide against human prostate, lung and breast tumor models.
    Mewani RR; Tang W; Rahman A; Dritschilo A; Ahmad I; Kasid UN; Gokhale PC
    Int J Oncol; 2004 May; 24(5):1181-8. PubMed ID: 15067340
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhanced antitumor activity of doxorubicin by naringenin and metformin in breast carcinoma: an experimental study.
    Pateliya B; Burade V; Goswami S
    Naunyn Schmiedebergs Arch Pharmacol; 2021 Sep; 394(9):1949-1961. PubMed ID: 34125254
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selective tumor sensitization to taxanes with the mAb-drug conjugate cBR96-doxorubicin.
    Wahl AF; Donaldson KL; Mixan BJ; Trail PA; Siegall CB
    Int J Cancer; 2001 Aug; 93(4):590-600. PubMed ID: 11477565
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination treatment with fulvestrant and various cytotoxic agents (doxorubicin, paclitaxel, docetaxel, vinorelbine, and 5-fluorouracil) has a synergistic effect in estrogen receptor-positive breast cancer.
    Ikeda H; Taira N; Nogami T; Shien K; Okada M; Shien T; Doihara H; Miyoshi S
    Cancer Sci; 2011 Nov; 102(11):2038-42. PubMed ID: 21801281
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metformin-induced preferential killing of breast cancer initiating CD44+CD24-/low cells is sufficient to overcome primary resistance to trastuzumab in HER2+ human breast cancer xenografts.
    Cufi S; Corominas-Faja B; Vazquez-Martin A; Oliveras-Ferraros C; Dorca J; Bosch-Barrera J; Martin-Castillo B; Menendez JA
    Oncotarget; 2012 Apr; 3(4):395-8. PubMed ID: 22565037
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rational combination therapy of vintafolide (EC145) with commonly used chemotherapeutic drugs.
    Reddy JA; Dorton R; Bloomfield A; Nelson M; Vetzel M; Guan J; Leamon CP
    Clin Cancer Res; 2014 Apr; 20(8):2104-14. PubMed ID: 24429878
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined Use of Metformin and Everolimus Is Synergistic in the Treatment of Breast Cancer Cells.
    Wang Y; Wei J; Li L; Fan C; Sun Y
    Oncol Res; 2014; 22(4):193-201. PubMed ID: 26351208
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination study of 1,24(S)-dihydroxyvitamin D2 and chemotherapeutic agents on human breast and prostate cancer cell lines.
    Wigington DP; Urben CM; Strugnell SA; Knutson JC
    Anticancer Res; 2004; 24(5A):2905-12. PubMed ID: 15517895
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metformin inhibits the growth of human pancreatic cancer xenografts.
    Kisfalvi K; Moro A; Sinnett-Smith J; Eibl G; Rozengurt E
    Pancreas; 2013 Jul; 42(5):781-5. PubMed ID: 23462329
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metformin sensitizes EGFR-TKI-resistant human lung cancer cells in vitro and in vivo through inhibition of IL-6 signaling and EMT reversal.
    Li L; Han R; Xiao H; Lin C; Wang Y; Liu H; Li K; Chen H; Sun F; Yang Z; Jiang J; He Y
    Clin Cancer Res; 2014 May; 20(10):2714-26. PubMed ID: 24644001
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quinacrine in endometrial cancer: Repurposing an old antimalarial drug.
    Kalogera E; Roy D; Khurana A; Mondal S; Weaver AL; He X; Dowdy SC; Shridhar V
    Gynecol Oncol; 2017 Jul; 146(1):187-195. PubMed ID: 28545688
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nontoxic suramin treatments enhance docetaxel activity in chemotherapy-pretreated non-small cell lung xenograft tumors.
    Lu Z; Wientjes TS; Au JL
    Pharm Res; 2005 Jul; 22(7):1069-78. PubMed ID: 16028007
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synergism between the anticancer actions of 2-methoxyestradiol and microtubule-disrupting agents in human breast cancer.
    Han GZ; Liu ZJ; Shimoi K; Zhu BT
    Cancer Res; 2005 Jan; 65(2):387-93. PubMed ID: 15695378
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Combination of Metformin and Valproic Acid Has a Greater Anti-tumoral Effect on Prostate Cancer Growth
    Tran LNK; Kichenadasse G; Morel KL; Lavranos TC; Klebe S; Lower KM; Ormsby RJ; Elliot DJ; Sykes PJ
    In Vivo; 2019; 33(1):99-108. PubMed ID: 30587609
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacious dose of metformin for breast cancer therapy is determined by cation transporter expression in tumours.
    Cai H; Everett RS; Thakker DR
    Br J Pharmacol; 2019 Aug; 176(15):2724-2735. PubMed ID: 31032880
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Flaxseed Lignans Enhance the Cytotoxicity of Chemotherapeutic Agents against Breast Cancer Cell Lines MDA-MB-231 and SKBR3.
    Di Y; De Silva F; Krol ES; Alcorn J
    Nutr Cancer; 2018; 70(2):306-315. PubMed ID: 29303360
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.